ReviewJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2020
Liver Transplantation for Peri-hilar Cholangiocarcinoma.
Review in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Can the Limits of Liver Transplantation Be Expanded in Perihilar Cholangiocarcinoma?Journal of gastrointestinal cancer · 2022Pooled it
- Transplantation for unresectable perihilar cholangiocarcinoma beyond the Mayo protocol: a challenge for SURE.Hepatobiliary surgery and nutrition · 2026Article
- Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review.Journal of clinical medicine · 2026Review
- Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma.Hepatology (Baltimore, Md.) · 2026Article
- Transplant Oncology in Evolution: Emerging Roles for Liver Transplant Beyond Hepatocellular Carcinoma.Cancers · 2026Review
- [Klatskin tumors-differentiated surgical treatment].Chirurgie (Heidelberg, Germany) · 2026Review
- Treatment of biliary tract cancer - essentials for clinical practice.Frontiers in oncology · 2026Review
- COMIT-ANZ: an audit of cholangiocarcinoma and mixed hepatocellular carcinoma-cholangiocarcinoma outcomes for patients undergoing liver transplantation in Australia and New Zealand.Frontiers in transplantation · 2026Article
- Present and future of liver transplantation for cholangiocellular carcinoma: moving toward personalized multiparametric transplantability patterns.Transplant international : official journal of the European Society for Organ Transplantation · 2026Review
- Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026Review
- Outcomes of Living-Donor Liver Transplantation for Cholangiocarcinoma Versus Hepatocellular Carcinoma in the United States.Journal of clinical medicine · 2025Article
- Review
- Review
- Article
- Cholangiocarcinoma: The Current Status of Surgical Options including Liver Transplantation.Cancers · 2024Review
- National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma.World journal of gastroenterology · 2024Review
- Update on the Screening, Diagnosis, and Management of Cholangiocarcinoma.Gastroenterology & hepatology · 2024Article
- Transplant oncology - Current indications and strategies to advance the field.JHEP reports : innovation in hepatology · 2024Review
- Liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma: A multicenter study.World journal of gastrointestinal surgery · 2023Article
- Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver transplantation for peri-hilar cholangiocarcinoma (pCCA) following neoadjuvant chemoradiation achieves excellent long-term survival in carefully selected patients with early-stage unresectable pCCA and patients with primary sclerosing cholangitis (PSC)-associated pCCA. Strict adherence to selection criteria, aggressive neoadjuvant therapy, operative staging prior to transplantation, and several technical accommodations during the transplant operation are necessary for success. In this review, we provide a contemporaneous overview of liver transplantation for pCCA, including selection criteria, neoadjuvant therapy, operative staging, and technical aspects of liver transplantation unique to patients with pCCA and an irradiated operative field. We also discuss several evolving trends intended to improve patient outcomes. RESULTS AND
conclusionIntention-to-treat and patient outcomes after liver transplantation for PSC-associated pCCA are superior to de novo pCCA. Outcomes between living donor liver transplantation (LDLT) and deceased donor liver transplantation are similar for patients with PSC-associated pCCA. However, LDLT for de novo pCCA shows a trend toward more disease recurrence and worse patient survival. A period of waiting time before transplant may be beneficial in selecting for patients with superior outcomes after transplant. Compared with liver transplantation for other indications, there is an increased risk of late arterial and portal vein complications, presumably due to the radiation. However, with close follow-up and prompt intervention for vascular complications, graft loss can be avoided. Neoadjuvant therapy and liver transplantation can achieve results comparable with resection for patients with early-stage unresectable pCCA and is the treatment of choice for patients with pCCA arising in the setting of PSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.